Navidea biopharmaceuticals announces acceptance of abstract for presentation at the society of nuclear medicine and molecular imaging annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “tam targeted imaging agents binding cd206 and selective blocking of off target liver localization” for presentation at this year's society of nuclear medicine and molecular imaging (“snmmi”) annual meeting. this work was performed as
NAVB Ratings Summary
NAVB Quant Ranking